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Availability of evidence of benefits on overall survival and quality 
of life of cancer drugs approved by European Medicines Agency: 
retrospective cohort study of drug approvals 2009-13
Courtney Davis,1 Huseyin Naci,2 Evrim Gurpinar,2 Elita Poplavska,3 Ashlyn Pinto,2  
Ajay Aggarwal4,5
ABSTRACT
OBJECTIVE
To determine the availability of data on overall survival 
and quality of life benefits of cancer drugs approved 
in Europe.
Design
Retrospective cohort study.
Setting
Publicly accessible regulatory and scientific reports on 
cancer approvals by the European Medicines Agency 
(EMA) from 2009 to 2013.
Main outcome measures
Pivotal and postmarketing trials of cancer drugs 
according to their design features (randomisation, 
crossover, blinding), comparators, and endpoints. 
Availability and magnitude of benefit on overall 
survival or quality of life determined at time of 
approval and after market entry. Validated European 
Society for Medical Oncology Magnitude of Clinical 
Benefit Scale (ESMO-MCBS) used to assess the 
clinical value of the reported gains in published 
studies of cancer drugs.
Results
From 2009 to 2013, the EMA approved the use of 
48 cancer drugs for 68 indications. Of these, eight 
indications (12%) were approved on the basis of a 
single arm study. At the time of market approval, 
there was significant prolongation of survival in 
24 of the 68 (35%). The magnitude of the benefit 
on overall survival ranged from 1.0 to 5.8 months 
(median 2.7 months). At the time of market approval, 
there was an improvement in quality of life in seven 
of 68 indications (10%). Out of 44 indications for 
which there was no evidence of a survival gain at 
the time of market authorisation, in the subsequent 
postmarketing period there was evidence for 
extension of life in three (7%) and reported benefit 
on quality of life in five (11%). Of the 68 cancer 
indications with EMA approval, and with a median of 
5.4 years’ follow-up (minimum 3.3 years, maximum 
8.1 years), only 35 (51%) had shown a significant 
improvement in survival or quality of life, while 
33 (49%) remained uncertain. Of 23 indications 
associated with a survival benefit that could be scored 
with the ESMO-MCBS tool, the benefit was judged 
to be clinically meaningful in less than half (11/23, 
48%).
Conclusions
This systematic evaluation of oncology approvals by 
the EMA in 2009-13 shows that most drugs entered 
the market without evidence of benefit on survival or 
quality of life. At a minimum of 3.3 years after market 
entry, there was still no conclusive evidence that 
these drugs either extended or improved life for most 
cancer indications. When there were survival gains 
over existing treatment options or placebo, they were 
often marginal.
Introduction
Before new prescription medicines are allowed onto 
the market, they must be tested in studies and show, to 
the satisfaction of drug regulatory agencies, that their 
benefits outweigh the harms of drug toxicity. The most 
informative and valuable studies are those providing 
robust evidence from well designed randomised 
controlled trials that a new drug has a significant effect 
on outcomes that are important to patients and that 
the magnitude of those effects, compared with other 
treatment options, are clinically meaningful. Although 
the goal of cancer treatment is to improve the quantity 
and quality of life,1 2 3 clinical trials designed to gain 
regulatory approval for new drugs often evaluate 
indirect or “surrogate” measures of drug efficacy. These 
endpoints show that an agent has biological activity, 
but they are not reliable surrogates for improved 
survival4-11 or quality of life4 6 11-13 in all settings, and 
two recent systematic reviews suggest that the strength 
of association between surrogates in cancer clinical 
trials and life extension is generally low.8 14 Moreover, 
there is growing concern that the benefits offered by 
many new treatments for cancer—often discussed and 
promoted as “breakthroughs”15-18—are marginal and 
might not be clinically meaningful to patients, despite 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Clinical trials designed to gain regulatory approval for new drugs often evaluate 
surrogate measures that do not always reliably predict clinically meaningful 
outcomes like survival or quality of life
Recent reviews from the US show that only a small proportion of cancer drugs 
approved by the US Food and Drug Administration improve survival or quality 
of life
No recent studies have systematically examined the evidence base for and 
magnitude of benefit for cancer drugs approved by the EMA
WhAT ThIS STudy AddS
Most new oncology drugs authorised by the EMA in 2009-13 came onto the 
market without clear evidence that they improved the quality or quantity of 
patients’ lives
After market entry, cancer drugs rarely show benefits on overall survival or 
quality of life in randomised trials
When survival gains over available treatment alternatives are shown, they are 
not always clinically meaningful
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rapidly escalating costs.19-23 Consequently, there 
have been calls to raise the evidence bar for market 
authorisation of new cancer drugs.15 21 23-26
No recent studies have systematically examined the 
evidence base and magnitude of benefit for cancer 
drugs approved by the European Medicines Agency 
(EMA).27-29 Available data from the US show that only a 
small proportion of cancer treatments approved by the 
US Food and Drug Administration (FDA) unequivocally 
show benefits on survival or quality of life.30 The 
applicability of this evidence to the European context, 
however, is not clear. Recent FDA-EMA comparisons 
show differences in regulatory decisions, route of 
approval, and availability of cancer drugs that could 
have important implications for clinical practice and 
patient safety.31-35 In particular, regulatory provisions 
for expediting drug development and approval differ 
between the US and the EU,32 with EU regulation being 
more restrictive in scope.36 This could lead to divergent 
outcomes between the two regions.
The proportion of cancer drugs approved by the 
EMA without any demonstrable benefits on survival 
or quality of life is not known. In addition, whether 
treatments approved without evidence of benefit on 
survival are subsequently shown to improve survival 
or quality of life in postmarketing studies has not been 
characterised.
We sought to systematically evaluate the evidence 
base for all new drugs and new indications for the 
treatment of solid tumours and haematological 
malignancies approved by the EMA in the five year 
period 2009-13. We determined the proportion of 
drugs with demonstrable benefit on survival or quality 
of life over available treatment options or placebo, both 
at time of approval and in the postmarketing period. 
In addition, we used a validated scale to evaluate the 
magnitude of benefit of drugs in our sample showing a 
significant improvement on survival in the treatment 
of solid cancers.
Methods
Cohort of cancer drugs approved by EMA 2009-13
We searched the publicly available EMA database 
of European Public Assessment Reports using 
L01-04 ATC codes to identify “antineoplastic and 
immunomodulating” agents for solid tumours and 
haematological malignancies authorised from 1 
January 2009 to 31 December 2013. Consistent with 
previous research,30 our study period ended in 2013, 
which allowed adequate time for the completion of 
randomised trials in the postmarketing period. We 
excluded paediatric indications, indications for the 
treatment of benign tumours, supportive treatments, 
and generic products (fig A in appendix). Authorised 
indications for each drug were identified by searching 
the EPAR document “Procedural steps taken and 
scientific information after authorisation.”
We distinguished between different types of 
regulatory approval. A “first marketing authorisation” 
indicates that the drug is a new active substance, 
approved onto the EU market for the first time. An 
“extension” to a marketing authorisation is when a 
marketed drug is approved for use in a new patient 
population, new combination, new line of treatment, 
or new type of cancer. By law, a “regular marketing 
authorisation” should be based on comprehensive 
evidence of quality, safety, and efficacy. “Conditional 
marketing authorisations” can be granted for drugs 
intended to treat patients with seriously debilitating or 
life threatening diseases and are expected to fulfil an 
unmet medical need. Conditional approvals are granted 
on the basis of less comprehensive data than required 
for a regular marketing authorisation, and companies 
are required to generate additional evidence in the 
postmarketing period.36 “Orphan drug” designation 
is granted for the treatment of rare cancers. We also 
categorised indications according to cancer site and 
stage of disease (specifically whether treatments were 
to be used in a curative or non-curative setting).
Data sources and search strategies
To determine the availability of evidence on overall 
survival and quality of life gains at time of market 
approval for the drugs in our cohort, we manually 
searched the EMA website to identify the relevant 
European Public Assessment Reports (EPARs). EPARs 
are official regulatory documents in the public domain 
that summarise the evidence base for a new drug 
or new indication and provide a justification for the 
EMA’s decision to grant a marketing authorisation 
or extension to the marketing authorisation. Clinical 
trial data supporting approval of each of the unique 
indications were retrieved from the EPARs. We included 
only data from those studies identified by the EMA as 
the main, or “pivotal,” studies supporting approval.
To determine whether drugs that did not show any 
survival gain at the time of approval were subsequently 
confirmed to improve survival or quality of life in 
the postmarketing period, we searched PubMed for 
randomised controlled trials reporting these outcomes 
for the relevant indications. Our search strategy 
included the drug name, approved indication, and 
search terms for the endpoints of interest (overall 
survival or quality of life or QoL or HRQoL) (fig B in 
appendix). We identified randomised controlled trials 
using the Cochrane Collaboration sensitivity and 
precision maximising search strategy for identifying 
randomised trials.37 When possible, we cross checked 
search results against the European Clinical Trials 
Database (EudraCT) and the US National Library of 
Medicine database of clinical trials (ClinicalTrials.
gov). Our latest search was on 31 March 2017, which 
allowed for at least 3.3 years for the completion and 
publication of clinical studies in the postmarketing 
period (median 5.4 years, maximum 8.1 years).
For those drugs associated with an overall survival 
gain at the time of approval or in the postmarketing 
period, we used the European Society for Medical 
Oncology’s (ESMO) Magnitude of Clinical Benefit 
Scale (ESMO-MCBS) to assess the clinical value 
of these gains as reported in published studies.38 
The ESMO-MCBS scale is a tool for evaluating the 
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clinical benefit of new treatments for solid tumours 
to facilitate the presentation of clear and unbiased 
statements regarding the relative clinical benefit of 
new treatments.
Data extraction, outcome variables, and data 
analysis
Three investigators (AP, EP, and EG) independently 
extracted data on and descriptively analysed the 
following trial features: characteristics of the 
participant population, study design (randomisation, 
crossover from experimental to control group, 
and blinding of investigators and participants), 
experimental and control groups, enrolment, primary 
and secondary endpoints, magnitude of benefit on 
survival and quality of life, and narrative interpretation 
of the findings. We classified comparators as active 
(in trials comparing drugs A versus B), add on (in 
trials comparing drugs A+B versus B alone), placebo, 
or none. Investigators cross checked each other’s 
data extraction. Difficulties or disagreements in 
interpretation were resolved by discussion and 
consensus among the three lead investigators (CD, HN, 
and AA). All data were also checked by the principal 
investigator (CD).
We judged that a drug had shown a survival benefit 
in its approved indication if, as reported in the EPAR or 
study publication, overall survival was the primary or 
secondary endpoint in a randomised controlled trial, 
and the difference in survival between the experimental 
and control arms was significant according to a 
prespecified statistical analysis. If an analysis was 
described as “exploratory” we considered it to be a post 
hoc analysis. Post hoc analyses (in which the hypotheses 
being tested were not specified before examination 
of the data) were accepted if the EMA specifically 
determined that these analyses provided evidence of a 
survival benefit. If a published study reporting results 
of a pivotal trial conflicted with the EMA’s assessment 
or other information contained in an EPAR, we made 
a determination consistent with the EPAR, unless the 
published study reported an updated analysis.
We considered that a drug had shown a benefit 
on quality of life in its approved indication when 
a significant difference was reported for an item 
or subscale derived from a validated quality of life 
instrument, even in the absence of a significant benefit 
with respect to the global score.
Determination of ESMO-MCBS score
Our scoring was limited to drugs for solid tumours as the 
ESMO scales are not intended for evaluation of drugs to 
treat haematological malignancies.38 Two investigators 
(AA and CD) independently graded individual trials 
based on published papers that reported a significant 
difference in overall survival (as a prespecified primary 
or secondary study endpoint) using the most recent 
version of the ESMO-MCBS evaluation forms.39 There 
was complete agreement between the two investigators 
in the scoring. As per the established ESMO methods, 
each score was assigned based on the magnitude 
of the absolute survival gain and the lower limit of 
the 95% confidence interval of the hazard ratio, and 
only significant changes in toxicity or quality of life 
parameters were used to modify the grades. Only 
scores of A or B (for treatments of curative intent), or 5 
or 4 (for treatments used in the non-curative/palliative 
setting) are defined as clinically meaningful according 
to the ESMO framework.
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. 
There are no plans to disseminate the results of the 
research to study participants or the relevant patient 
community.
Results
From 2009 to 2013, the EMA approved use of 48 
oncology drugs in 68 indications. Of the authorised 
indications for use, 33 were first marketing 
authorisations and 35 were extensions (see methods 
for definitions) Table 1and table A in the appendix 
show the approved indication and the date and type 
of market authorisation for each agent. Some 58 uses 
were granted a regular marketing authorisation, of 
which seven were designated as orphan drugs. Ten 
uses were granted conditional marketing authorisation 
(including four designated as orphan drugs). In total, 
11/68 (16%) uses received orphan designation. 
Approval for one (bevacizumab in combination with 
docetaxel for the treatment of metastatic breast cancer) 
was subsequently withdrawn.40
Seventeen drugs were approved for treatment of 
haematological malignancies and 51 for treatment of 
solid tumours. Of these 51, 12 (24%) were for breast 
cancer, seven (14%) for lung cancer, five for bowel 
cancer, and five (10%) for prostate cancer. Of the 
17 drugs approved for treatment of haematological 
malignancies, four (24%) were for chronic myeloid 
leukaemia, three (18%) for multiple myeloma, and 
three (18%) for chronic lymphocytic leukaemia. Most 
drugs (61/68, 90%) were approved for use in a non-
curative setting (table 1).
Characteristics of pivotal studies
Overall, 72 clinical trials supported the approval of 
68 novel drug uses. Only 18 of the 68 (26%) were 
supported by a pivotal study powered to evaluate 
overall survival as the primary outcome (table 2 and 
table B in appendix). Survival was evaluated as the 
primary study endpoint in none of the 10 conditionally 
authorised uses and in only one of the 11 (9%) with an 
orphan designation. Overall survival was evaluated as 
a primary study endpoint in less than a third (18/58, 
31%) of all drug indications granted regular marketing 
authorisation.
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The remaining drug indications were supported by 
trials that evaluated a surrogate measure as the primary 
study outcome (table 2 and table B in appendix). This 
included progression-free survival for 31 (46%); 
response rate (including cytogenetic, haematological, 
and molecular response rates for haematological 
indications) for 11 (16%); disease-free survival for four 
(6%); with time to progression, event-free survival, 
relapse-free survival, and testosterone concentrations 
accounting for the remainder (4/68, 6%).
Just over half (37/68, 54%) of all drug indications 
had a supporting pivotal trial evaluating quality of 
life, but results were reported for only 35. None of 
the pivotal trials assessed quality of life as a primary 
endpoint (table 2).
Of 68 drug indications, 60 (88%) were supported 
by at least one randomised controlled trial, while 
eight of 68 (12%) were approved solely on the basis 
of a single arm study (6/10 indications granted a 
conditional marketing authorisation and 2/58 granted 
a regular marketing authorisation) (table 2 and table 
B in appendix). Most (6/8, 75%) authorised uses 
supported by uncontrolled studies were also orphan 
designations. On the other hand, more than half of the 
orphan drugs in our cohort (7/11, 64%) were approved 
on the basis of a randomised trial.
Availability of evidence on overall survival and 
quality of life at time of market authorisation
At time of market approval, according to the EPARs, 
there was significant prolongation of survival in just 
over a third (24/68, 35%) of all drug indications 
(including 3/17 drugs to treat haematological 
malignancies and 21/51 drugs to treat solid tumours). 
There were gains in survival for seven compared with 
an active comparator, eight compared with placebo, 
one compared with best supportive care, and eight 
as add on treatment. The magnitude of the overall 
survival benefit ranged from 1.0 to 5.8 months (median 
2.7 months) (fig 1). For the 44 (65%) remaining drug 
indications, there was no conclusive evidence at time 
of market authorisation that the drugs offered survival 
benefits, either as add on treatment or compared 
with placebo or existing treatment options in their 
authorised use.
Availability of evidence on overall survival and 
quality of life in postmarketing period
Of the 44 drug indications that did not show a survival 
benefit at time of approval, and with a median of 5.4 
years’ follow-up (minimum of 3.3 years and maximum 
of 8.1 years), three (7%) were subsequently shown 
to extend life after market entry and five (11%) were 
associated with some improvements in quality of life 
(fig 2).
For all three drug indications with a reported 
survival gain in the postmarketing period, evidence 
came from updated analyses of the pivotal studies 
supporting initial marketing authorisation, and all had 
been granted regular marketing approval. None of the 
10 drugs granted conditional marketing authorisation 
were subsequently shown to improve quantity or 
quality of life. One of 68 authorised uses judged by 
the EMA to extend life at time of market authorisation 
failed to show such a benefit on longer follow-up 
according to the published report.41 Thus, with a 
minimum 3.3 years’ follow-up, in 26 of the 68 (38%) 
authorised drug indications there was a survival gain 
(including three of the seven drugs approved for use in 
a curative setting).
For the five drug indications with a reported 
improvement in quality of life, evidence came from 
new studies in the same indicated population with the 
exception of nilotinib, for which a published paper42 
reporting the pivotal study described quality of life 
gains not reported in the EPAR. Box 2 lists those drugs 
not shown to extend life, but which were associated 
with a quality of life benefit with a median of 5.4 years’ 
follow-up.
Proportion of EMA oncology approvals meeting 
ESMO threshold for clinically meaningful survival 
benefit
Table 3 shows the ESMO-MCBS scores for all the 
drugs to treat solid tumours that showed benefit on 
overall survival by the time of our study cut off. After 
a median of 5.4 years’ follow-up 26 drug indications 
were associated with a survival gain, but three of these 
were for haematological cancers, leaving a total of 23 
to which the ESMO scale could be applied.
Of these 23 drugs, 11 (48%) reached the ESMO 
threshold for a meaningful survival benefit; eight out 
Table 1 | Characteristics of approvals of cancer drug, 2009-13. Figures are numbers 
(percentage) of indications
Characteristics Solid tumours (n=51)
Haematological  
tumours (n=17)
Type of marketing authorisation:
 First marketing authorisation 24 (47) 9 (53)
 Extension 27 (53) 8 (47)
Pathway of first marketing authorisation:
 Regular approval 19 (79) 4 (44)
 Conditional approval 5 (21) 5 (56)
 Orphan designation 3 (6) 8 (47)
Intent of treatment:
 Curative 6 (12) 1 (6)
 Non-curative 45 (88) 16 (94)
Table 2 | Characteristics of pivotal trials of cancer drugs. Figures are numbers 
(percentage) unless stated otherwise
Characteristics Solid tumours (n=54)
Haematological  
tumours (n=18)
Pivotal trial design:
 Randomised trial 52 (96) 13 (72)
 Single arm trial 2 (4) 5 (28)
Comparator:
 Active 15 (28) 9 (50)
 Placebo 25 (46) 0 (0)
 Add on 12 (22) 4 (22)
 None 2 (4) 5 (28)
 OS as primary endpoint 18 (33) 1 (6)
 OS or QoL as secondary endpoint 47 (87) 17 (94)
 Median (range) sample size 696 (96-3222) 484 (58-1018)
OS=overall survival; QoL=quality of life.
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Fig 1 | Magnitude of 
overall survival benefit at 
the time of EMA approval. 
Figure excludes seven 
indications for which 
median overall survival 
could not be estimated 
at time of marketing 
authorisation: mifamurtide 
for resectable non-
metastatic osteosarcoma 
after complete resection 
(+chemo); pertuzumab 
for 1st line HER2+mBC; 
pomalidomide for 3rd 
line (+dexamethasone) 
relapsed and refractory 
multiple myeloma; 
rituximab for 1st line CLL 
(+chemo); trastuzumab 
for HER2+ BC (+taxane) 
after adjuvant chemo; 
trastuzumab for HER2+BC 
(+adjuvant chemo); 
and trastuzumab for 
HER2+locally advanced 
BC (+neoadjuvant chemo 
and as monotherapy 
adjuvantly). Box 1 shows 
abbreviations used
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Box 1: Abbreviations used in tables and figures
5FU=5 fluorouracil; adenoca=adenocarcinoma; AI=aromatase inhibitor; ALCL=anaplastic large cell lymphoma; ALK=anaplastic lymphoma kinase; 
ALL=acute lymphoblastic leukaemia; AML=acute myeloid leukaemia; AP=accelerated phase; ASCT=autologous stem cell transplant; BC=breast 
cancer; BCC=basal cell carcinoma; BP=blast phase; chemo: BCS=best supportive care; chemo=chemotherapy; CLL=chronic lymphocytic 
leukaemia; CML=chronic myelogenous leukaemia; CP=chronic phase; EFGR=epidermal growth factor receptor; EGFRi=epidermal growth factor 
receptor inhibitor; FOLFIRI: irinotecan/5 fluorouracil/folinic acid; FOLFOX: oxaliplatin/5 fluorouracil/folinic acid; GC=gastric cancer; 
GIST=gastrointestinal stromal tumours; HL=Hodgkin lymphoma; HR=hormone receptor; mBC=metastatic breast cancer; MCL=mantle cell 
lymphoma; mCRC=metastatic colorectal cancer; mCRPC=metastatic castration resistant prostate cancer; mGC=metastatic gastric cancer; 
mGOJ=metastatic gastric or esophageal junction; mNSCLC=metastatic non-small cell lung cancer; mPC=metastatic prostate cancer; 
mut=mutation; non-squam=non-squamous; PBO=placebo; NHL=non-Hodgkin lymphoma; NR=not reported; PC=prostate cancer; 
Ph+=Philadelphia chromosome positive; PLD=pegylated liposomal doxorubicin; PNET=pancreatic neuroendocrine tumours; pred=prednisone or 
prednisolone; RCC=renal cell carcinoma; SCT=stem cell transplantation; squam=squamous; STS=soft tissue sarcoma; TC=thyroid cancer; 
TCC=transitional cell carcinoma; TKI=tyrosine kinase inhibitor; VEGFi=vascular endothelial growth factor inhibitor; WT=wild-type
There was a significant improvement in quality of life over the control arm in only seven of the 68 (10%) authorised drug indications. Five of these 
were drug indications for which there was no survival gain at the time of market authorisation, giving a total of 29 of 68 (43%) that did show 
improvements in either quantity or quality of life at time of market entry.
The remaining 39 (57%) drugs had shown no improvement in survival or quality of life over active treatment, placebo, or as add on treatment. 
Eleven were evaluated against an active comparator, and 10 of these had comparable efficacy with respect to survival, although in most cases 
survival data were immature. Twenty were evaluated against placebo or as add on treatment and showed no gains in survival or quality of life. Eight 
were approved on the basis of a single arm trial.
Degarelix
Rituximab
Mifamurtide
Imatinib
Getinib
Pemetrexed
Bevacizumab
Everolimus
Rituximab
Vinflunine
Temsirolimus
Trabectedin
Trastuzumab
Ofatumumab
Erlotinib
Lapatinib
Pazopanib
Pazopanib
Docetaxel
Rituximab
Sunitinib
Dasatinib
Nilotinib
Tegafur/gimeracil/oteracil
Cabazitaxel
Eribulin
Trastuzumab
Trastuzumab
Bevacizumab
Ipilimumab
Erlotinib
Everolimus
Abiraterone acetate
Pemetrexed
Panitumumab
Panitumumab
Bevacizumab
Trastuzumab
Cetuximab
Vandetanib
Vemurafenib
Pixantrone
Everolimus
Pazopanib
Axitinib
Decitabine
Crizotinib
Bevacizumab
Brentuximab vedotin
Brentuximab vedotin
Abiraterone acetate
Aflibercept
Pertuzumab
Bosutinib
Enzalutamide
Ponatinib
Ponatinib
Vismodegib
Lapatinib
Bortezomib
Pomalidomide
Dabrafenib
Regorafenib
Afatinib
Ipilimumab
Trastuzumab emtansine
Nab-paclitaxel
Bortezomib
Agent
Advanced PC
1st line CLL (+chemo)
Resectable non-metastatic osteosarcoma aer complete resection (+chemo)
Adjuvant treatment for high risk GIST
EGFR mut+mNSCLC
Maintenance for mNSCLC (non-squam) aer platinum based doublet chemo (w/gemcitabine or taxane)
1st line mBC (+docetaxel)
Advanced RCC aer VEGF targeted treatment
Relapsed/refractory CLL (+chemo)
Advanced or metastatic TCC of urethral tract. Previous platinum regimen
Relapsed or refractory MCL
Relapsed (platinum sensitive) ovarian cancer (+PLD)
1st line HER2+mGC or mGOJ adenoCa
CLL refractory to fludarabine and alemtuzumab
Maintenance therapy in mNSCLC (previous platinum based chemo)
HER2+HR+mBC (+aromatase inhibitor). No previous chemo, trastuzumab, or AI)
1st line advanced RCC
2nd line advance RCC (previous cytokine)
Adjuvant treatment of operable node negative BC (+doxorubicin and cyclosphamide)
Maintenance therapy for follicular lymphoma aer induction
2nd line unresectable or metastatic well dierentiated PNET
1st line Ph+CML (CP)
Newly diagnosed adult Ph+CML (CP)
Advanced GC (+cisplatin)
Hormone refractory mPC (+pred) previously treated with docetaxel
3rd line mBC
HER2+BC (+taxane) aer adjuvant chemo
HER2+BC (+ adjuvant chemo)
1st line mBC (+capecitabine). No previous taxanes or anthracyclines
2nd line unresectable or metastatic melanoma
1st line EGFR mut+mNSCLC
Unresectable or metastatic well or moderately dierentiated PNET
mCRPC (+pred) aer chemo
Maintenance for mNSCLC (non-squam) aer platinum based chemo
1st line KRAS WT mCRC (+FOLFOX)
2nd line KRAS WT mCRC (+FOLFIRI) 
1st line (+carboplatin and paclitaxel) in stage IIIB ovarian, fallopian, or primary peritoneal cancer
HER2+ locally advanced BC (+neoadjuvant chemo and as monotherapy adjuvantly)
1st line KRAS WT mCRC (+FOLFOX)
Unresectable or metastatic medullary TC
Unresectable of metastatic melanoma (BRAF V600 mit)
Multiple relapsed or refractory NHL (B cell)
2nd line HER2/nue-negative BC (+exemetane)
Advanced STS (aer chemo or progressed within 12 months aer neo-adjuvant therapy)
2nd line advanced RCC
1st line AML in adults aged ≥65 ineligible for chemo
2nd line ALK+advanced NSCLC
2nd line (+carboplatin and gemcitabine) platinum sensitive ovarian, fallopian, or primary peritoneal cancer. No previous VEGFi
Relapsed or refractory CD30+HL aer ASCT or 3rd line if ineligible for ASCT
Relapsed or refractory systemic ALCL
mCRPC (+pred) before chemo
2nd line mCRC (+FOLFIRI)
1st line HER2+mBC
2nd or 3rd line CP, AP, BP, Ph+, or CML
mCRPC previously treated with docetaxel
CML (CP, AP, BP) resistant or intolerant to dasatinib or nilotinib or with T3151 mutation or ineligible for imatinib
Ph+ALL resistant or intolerant to dasatinib or with T3151 mutation or ineligible for imatinib
mBCC
HER2+HR- mBC (+trastuzumab). Previous trastuzumab+chemo
1st line multiple myeloma eligible for SCT (+dexamethasone or dexamethasone+thalidomide)
3rd line (+dexamethasone) relapsed and refractory multiple myeloma
Unresectable or metastatic melanoma w/BRAF V600 mut
mCRC either aer previous treatment with/ or ineligible for 5FU based chemo or VEGFi or EGFRi treatment
TKI naive EGFR mut+mNSCLC
1st line unresectable or metastatic melanoma
HER2+ unresectable or mBC aer trastuzumab and/or taxane treatment
1st line (+gemcitabine) metastatic pancreatic adenoca
2nd line multiple myeloma ineligible for SCT (monotherapy or +doxorubicin or dexamethasone)
Indication
01/2009 06/2010 10/2011 02/2013 07/2014 11/2015 04/2017
Time of market approval
OS benet at time of market approval
QoL benet at time of market approval
OS benet in postmarketing period
Qol benet in postmarketing period
Fig 2 | Availability of benefits on overall survival and quality of life of cancer drugs approved 2009-13. Box 1 shows abbreviations used
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Box 2: Cancer drugs associated with benefit on health related quality of life (HRQoL)
Reported at time of market approval
•   Afatinib v pemetrexed/cisplatin (for the treatment of TKI-naive, EGFR mutation +ve, non-small cell lung cancer) significantly delayed the time to 
deterioration for cough and dyspnoea but not time to deterioration of pain. HRQoL was evaluated against prespecified components of the 
European Organisation for Research and Treatment of Cancer quality of life questionnaire C30 (EORTC QLQ-C30) questionnaire and lung cancer 
module QLQ-LC13. The study was open label43
•   Gefitnib (for the treatment of metastatic non-small cell lung cancer) showed significant benefits on quality of life compared with carboplatin plus 
paclitaxel, and with docetaxel on some measures, but not compared with placebo. HRQoL was assessed with the functional assessment of 
cancer therapy-lung (FACT-L), and trial outcome index (TOI), and symptom improvement by the lung cancer subscale (LCS). The active comparator 
trials were open label. The trial v placebo was double blind44
•   Tegafur, gimeracil, oteracil (S-1) (in combination with cisplatin for the treatment of advanced gastric cancer) showed a significant improvement 
over cisplatin/5-fluorouracil for only one of the subscales (physical wellbeing) of the functional assessment of cancer therapy-gastric (FACT-Ga) 
HRQOL instrument. The study was open label45
•   Vandetanib v placebo (for the treatment of metastatic medullary thyroid cancer) significantly improved “time to worsening of pain” (a composite 
endpoint based on patient reported analgesic use and responses to the brief pain inventory) but did not show a significant improvement for the 
functional assessment of cancer therapy-general (FACT-G) score. The study was double blind46
Reported in the postmarketing period
•   Crizotinib (for second line treatment of ALK mutation +ve advanced non-small cell lung cancer) showed significant improvements compared with 
pemetrexed across a range of HRQoL measures, including a significantly greater delay in time to worsening of symptoms. HRQoL was assessed 
with the European Organisation for Research and Treatment of Cancer quality of life questionnaire C30 (EORTC QLQ-C30) and the lung cancer 
module QLQ-LC13. The study was open label47
•   Erlotinib (for first line treatment of EGFR mutation +ve metastatic non-small cell lung cancer) showed clinically relevant and significant 
improvements compared with gemcitabine/carboplatin in total functional assessment of cancer therapy-lung (FACT-L), trial outcome index (TOI), 
and lung cancer subscale (LCS) scores. The study was open label48
•   Nilotinib v imatinib (for patients with newly diagnosed Ph+ chronic myeloid leukaemia) reported a significant quality of life improvement with 
respect to some categories of low grade adverse events. HRQoL was assessed with generic SF-36 and leukaemia specific functional assessment 
of cancer therapy-leukaemia (FACT-Leu) surveys. The study was open label42
•   Ofatumumab (in patients with chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab) showed significant improvements v 
“physician’s choice” with respect to fatigue but not side effects of treatment or effects of disease. HRQoL was evaluated according to three 
prespecified domains of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-C30) and the 
chronic lymphocytic leukaemia module QLQ-CLL16 (fatigue, side effects of treatment, and effects of disease). The study was open label49
•   Pazopanib (for first line treatment of advanced renal cell carcinoma) significantly improved HRQoL compared with sunitinib with respect to 11 of 
14 HRQoL domains. HRQoL was assessed with the functional assessment of chronic illness therapy-fatigue (FACIT-F) questionnaire, the National 
Comprehensive Cancer Network/functional assessment of cancer therapy-kidney symptom index 19 (NCCN-FACT FKSI-19), and the cancer therapy 
satisfaction questionnaire. The study was open label50
of 20 (40%) for use in the non-curative setting and all 
three treatments with curative intent.
Results summary
Among 68 cancer drug indications approved by the 
EMA in the period 2009-13, and with a median of 5.4 
years’ follow-up, only 35 (51%) were associated with a 
significant improvement in survival (26/35) or quality 
of life (9/35) over existing treatment options, placebo, 
or as add on treatment. Only two of the 26 drugs shown 
to extend life also showed benefits on quality of life, 
and 33 (49%) had not shown any improvement on 
survival or quality of life (fig 2). Of the 23 drugs with a 
survival benefit that could be scored with the validated 
ESMO-MCBS tool, only 11 (48%) were judged to offer a 
clinically meaningful benefit.
discussion
Summary of findings
This systematic evaluation of oncology drug approvals 
by the EMA in 2009-13 shows that most of the drugs 
(39/68, 57%) entered the market without evidence of 
improved survival or quality of life. At a minimum 3.3 
years after market entry, there was still no conclusive 
evidence that 33 of these 39 cancer drugs either 
extended or improved life. Our findings suggest it is 
extremely rare for new studies or follow-up analyses 
of pivotal trials in the postmarketing period to report 
results confirming that new cancer drugs have a 
positive impact on the two most important outcomes 
for patients—survival and quality of life. When survival 
gains over existing treatment options or placebo were 
shown, they were often marginal and judged to be 
clinically meaningful in less than half (11/23, 48%) of 
all cases.
What are potential reasons for the paucity of drug 
approvals with demonstrable survival advantages over 
existing treatments? Firstly, only 18 (26%) indications 
for use in our cohort were supported by trials in which 
extension of life was the primary outcome, and trials 
that evaluated survival as a secondary endpoint might 
not have been powered to detect differences between 
groups with and without the experimental treatment. 
Secondly, crossover from control to experimental 
arm after disease progression (or to similar drugs 
after the study) is a commonly cited reason for the 
lack of survival benefits in clinical trials of oncology 
products.38 It should be noted, however, that for some 
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Table 3 | ESMO grades for 23 drugs used to treat solid tumours that showed benefit on overall survival after follow-up
Study Drug Site Indication Trial
Overall 
survival 
gain* HR (CI)
QoL/ 
toxicity†
ESMO 
score‡
Fizazi (2012)51 Abiraterone Prostate mCRPC (+pred) after 
chemo
COU-AA-301 (pred-
nisone±abiraterone)
4.6 0.74 (0.64 to 0.86) Yes 4
Ryan (2015)52 Abiraterone Prostate mCRPC (+pred) before 
chemo
COU-AA-302 (abi-
raterone+prednisone 
or prednisolone v 
placebo+prednisone or 
prednisolone)
4.4 0.81 (0.70 to 0.93) Yes 4
Van Cutsem (2012)53 Aflibercept Bowel 2nd line mCRC (+FOL-
FIRI)
VELOUR (aflibercept, 
then FOFIRI v placebo, 
then FOLFIRI)
1.44 0.817 (0.713 to 0.937) No 1
De Bono (2010)54 Cabazitaxel Prostate Hormone refractory 
mPC (+pred) previously 
treated with docetaxel
TROPIC (cabazitax-
el+prednisone or 
prednisolone v mitox-
antrone+prednisone or 
prednisolone)
2.4 0.70 (0.59 to 0.83) No 2
Cortes (2011)55 Eribulin Breast 3rd line mBC EMBRACE (eribulin v 
physician’s choice)
2.5 0.81 (0.66 to 0.99) No 2
Cappuzzo (2010)56 Erlotinib Lung Maintenance therapy in 
mNSCLC (previous plat-
inum based chemo)
SATURN (erlotinib v 
placebo)
1 0.81 (0.70 to 0.95) No 1
Scher (2012)57 Enzalutamide Prostate mCRPC after docetaxel AFFIRM (enzalutamide v 
placebo)
4.8 0.63 (0.53 to 0.75) Yes 4
Hodi (2010)58 Ipilimumab Skin 2nd line unresectable 
or metastatic mela-
noma
MDX010-20 (ipilimum-
ab v vaccine alone)
3.7 0.66 (0.51 to 0.87) No 4
Robert (2011)59 Ipilimumab Skin 1st line unresectable or 
metastatic melanoma
CA184-024 (dacarba-
zine±ipilimumab)
2.1 0.72 (0.59 to 0.87) No 2
Blackwell (2012)60 Lapatinib Breast HER2+ HR- mBC (+ 
trastuzumab). Previous 
trastuzumab + chemo
EGF104900 (lapatin-
ib±trastuzumab)
4.5 0.74 (0.57 to 0.97) No 4
Meyers (2008)61 Mifamurtide Osteosarcoma Resectable, non-meta-
static osteosarcoma af-
ter complete resection 
(+ chemo)
INT-0133 6 years; 
8%
0.71 (0.52 to 0.96) NR A
Goldstein (2015)62 Nab-paclitaxel Pancreatic 1st line (+ gemcit-
abine) metastatic 
pancreatic adenoca
CA046 (gemcitabi-
ne±nab-paclitaxel)
2.1 0.72 (0.62 to 0.83) No 2
Douillard (2014)63 Panitumumab Bowel 1st line KRAS WT mCRC 
(+ FOLFOX)
PRIME (FOLFOX4±pani-
tumumab)
4.4 0.83 (0.70 to 0.98) No 3
Ciuleanu (2009)64 Pemetrexed Lung Maintenance for 
mNSCLC (non-squam) 
after platinum based 
doublet chemo (w/
gemcitabine or taxane)
JMEN (pemetrexed+BSC 
v placebo+BSC)
2.8 0.79 0.65 to 0.95) No 3
Paz-Ares (2013)65 Pemetrexed Lung Maintenance for 
mNSCLC (non-squam) 
after platinum based 
chemo
PARAMOUNT (peme-
trexed+BSC v place-
bo+BSC)
2.9 0.78 (0.64 to 0.96) No 3
Swain (2015)66 Pertuzumab Breast 1st line HER2+ mBC CLEOPATRA (trastuzuma-
b+chemo±pertuzumab)
15.7 0.68 (0.56 to 0.84) No 4
Grothey (2013)67 Regorafenib Bowel mCRC either after pre-
vious treatment with/
or ineligible for 5FU-
based chemo or VEGFi 
or EGFRi therapy
CORRECT (regorafenib v 
placebo)
1.4 0.77 (0.64 to 0.94) No 1
Bang (2010)68 Trastuzumab Stomach 1st line HER2+ mGC or 
mGOJ adenoca
ToGA (5-FU or capecit-
abine+cisplatin±trastu-
zumab)
2.7 0.74 (0.60 to 0.91) No 3
Perez (2014)69 Trastuzumab Breast HER2+ BC (+taxane) 
after adjuvant chemo
NASBP-31 and 
NCCTG-N9831 (dox-
orubicin+cyclophos-
phamide, followed by 
paclitaxel±trastuzumab)
10 years; 
8.8%
0.63 (0.54 to 0.73) NR A
Slamon (2011)70 Trastuzumab Breast HER2+ BC (+adjuvant 
chemo)
BCIRG-006 (doxo-
rubicin+cyclophos-
phamide, followed 
by trastuzumab v 
doxorubicin+cyclophos-
phamide, followed by 
docetaxel)
5.4 years; 
5%
0.63 (NR) No B
(Continued)
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Table 3 | ESMO grades for 23 drugs used to treat solid tumours that showed benefit on overall survival after follow-up (Continued)
Study Drug Site Indication Trial
Overall 
survival 
gain* HR (CI)
QoL/ 
toxicity†
ESMO 
score‡
Verma (2012)71 Trastuzumab 
emtansine
Breast HER2+ unresectable or 
mBC after trastuzumab 
and/or taxane
EMILIA (trastuzumab 
emanstine v lapatinib+-
capecitabine)
5.8 0.68 (0.55 to 0.85) Yes 5
McArthur (2014)72 Vemurafenib Skin Unresectable or meta-
static melanoma (BRAF 
V600 mut)
BRIM-3 (vemurafenib v 
dacarbazine)
3.9 0.70 (0.57 to 0.87) No 4
Bellmunt (2009)73 Vinflunine Urinary Advanced or metastatic 
TCC of urothelial tract. 
Previous platinum 
regimen
VFL-302 (vinflunine+B-
SC v BSC)
2.6 0.77 (0.61 to 0.99) No 3
See box 1 for abbreviations.
*Survival gain in months, or percent of patients surviving at x years.
†Yes=quality of life or improved toxicity reported; no=no quality of life gain or improvement in toxicity reported, or toxicity might be worse.
‡For drug indications with curative intent, grade of A or B indicates trial data show drug offers clinically meaningful benefit. For drug indications with non-curative intent, grade of 4 or 5 indicates 
trial data show drug offers clinically meaningful benefit. For drugs with non-curative intent, grade of 1, 2, or 3 indicates drug does not reach ESMO threshold for clinically meaningful benefit.
indications for use in our cohort there were no survival 
gains even in the absence of crossover.7 50 74-76
None of the pivotal studies supporting oncology 
drug approvals from 2009 to 2013 included quality 
of life as a primary outcome measure. This is perhaps 
unsurprising as the EMA does not require marketing 
authorisation holders to evaluate quality of life, even 
when drugs are intended for late line palliative care.77 
Of the 68 (54%) study indications, 37 were supported 
by a pivotal trial in which quality of life was evaluated 
as a secondary endpoint, and for only seven (10%) 
was there a significant improvement in quality of 
life at time of market entry. Neither the EPARs nor 
the published studies were consistent in reporting 
whether significant improvements for specific quality 
of life outcomes were also clinically relevant. These are 
particularly troubling findings as many of the drugs in 
our sample were approved to treat advanced metastatic 
disease, when the purpose of treatment is palliative—
that is, to improve quality of life—or to extend life while 
ensuring that any survival gains are not outweighed by 
a deterioration in quality of life from adverse events or 
other negative factors related to treatment.78 79
A significant minority of drugs in our sample (8/68, 
12%) were approved solely on the basis of a single 
arm study. Most of the indications supported by single 
arm studies (6/8) were granted orphan designation, 
and it is recognised that the conduct of randomised 
trials to investigate treatments for rare cancers can be 
challenging. Nevertheless, a review of FDA approvals 
indicates that randomised controlled trials are feasible 
even in rare cancers with an incidence of less than 
1/100 000/year.80
Comparison with other studies
Apolone and colleagues27 evaluated the evidence 
base for new cancer drugs approved by the EMA in 
the period 1995-2004. In that 10 year period the EMA 
authorised 14 anticancer drugs for 27 indications. 
An important difference between their earlier study 
and the present one is that the earlier cohort includes 
only drugs to treat solid tumours. Nevertheless, our 
findings indicate some improvements in the quality 
of the evidence base supporting new oncology drugs. 
For example, drug uses authorised in the study period 
2009-13 were more likely to be supported by trials that 
included overall survival as a primary endpoint (26% v 
8%), and by randomised trials (88% v 66%). There has 
been a substantial increase in the number of approved 
treatments for solid tumours compared with the earlier 
period—an average of 12 a year for 2009-20 compared 
with three a year for 1995-2004.
In contrast with recent studies focusing on a subset 
of oncology drug approvals in Europe,32 33 we included 
all authorised oncology indications regardless of route 
of approval and systematically analysed survival 
and quality of life benefits. We also relied exclusively 
on evidence generated from randomised controlled 
trials. We did not therefore accept mathematical 
models considered by health technology assessment 
bodies such as the National Institute for Health and 
Care Excellence.81 There is continuing debate around 
the validity of simulation models that extrapolate 
findings from short term trials.82 83 Our analysis is the 
first to investigate whether drugs that did not show a 
survival benefit at the time of approval in Europe are 
subsequently shown to improve survival or quality 
of life in follow-up randomised controlled trials once 
drugs are on the market.
Study limitations
There are several limitations to this study. Firstly, 
there were several cases in which results reported 
in the EPARs were ambiguous or incomplete. When 
difficulties in interpretation occurred, we ensured 
our determinations were consistent with the EMA’s 
conclusions. Following this approach, we determined 
that significant survival benefits had been shown 
at time of market authorisation for vinflunine (in 
transitional cell carcinoma) and trastuzumab (in 
neoadjuvant breast cancer), despite uncertainty 
regarding the reported statistical analyses. When the 
EMA’s opinions on specific questions were not clear 
or not available, we adopted a generous approach 
that favoured the drug. For example, we credited 
panitumumab with showing a survival benefit in the 
postmarketing period on the basis of an “exploratory” 
analysis.84
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There was also considerable variation in the 
reporting of quality of life endpoints in both the 
EPARs and the medical literature. Significant results 
might have been shown for isolated parameters or 
single subscales only, and it was not clear whether a 
net quality of life benefit had been shown. Nor was it 
consistently reported whether or not the magnitude 
of improvement was such that it would be considered 
clinically meaningful for patients. Consequently, we 
might have overestimated the proportion of drugs 
that offer benefits on survival or quality of life and 
the clinical meaningfulness of these. Our findings, 
however, are consistent with recent findings from 
the US.30  85
Secondly, we did not consider the appropriateness 
of clinical trial design, including whether a treatment 
administered in the control arm of a study was 
optimal or even informative. This is an important 
study limitation, which again means we might have 
overestimated the benefits offered by the drugs in our 
sample. For example, the control arm of the pivotal 
trial to support approval of ipilimumab for metastatic 
melanoma was an experimental treatment. Similarly, 
the pivotal trial to support lapatinib in combination 
with trastuzumab for patients with metastatic 
breast cancer used lapatinib monotherapy as the 
comparison—a treatment acknowledged in the EPAR 
to be “without established efficacy.”86 Although this 
trial design failed to isolate the effects of the test drug, 
the EMA nevertheless concluded that the reported 
benefit in survival was clinically relevant and could be 
attributed to the combination.
Thirdly, our ESMO ratings share the limitations of 
the published studies on which they are based. For 
example, the magnitude of clinical benefit shown in 
a particular trial could be inflated by the choice of an 
inappropriate comparator or treatment in the control 
arm that does not represent best standard of care.38 
Several maintenance therapy trials for metastatic 
non-small cell lung cancer, for example, have been 
criticised for flawed study designs that systematically 
result in substandard care in the control arms.87 In 
the case of lapatinib combined with tratuzumab, the 
pivotal study was scored 4 on the basis of a 4.5 month 
survival gain over lapatinib monotherapy (with no 
established efficacy).
Fourthly, our findings do not reflect the totality of 
the evidence base for a specific authorised indication 
as we did not take account of studies with negative 
results for the same drug indication if they were not 
reported as pivotal studies in the EPAR, nor did we take 
account of the fact that studies with positive results for 
a particular indication could conflict with negative 
findings from other studies in the same indicated 
patient population.
Implications for clinical practice and regulatory 
policy 
Despite the EMA’s statement that overall survival is the 
“most persuasive outcome” for studies investigating 
the clinical safety and efficacy of new oncology drugs 
and new uses of such drugs, European regulators 
commonly accept the use of surrogate measures of 
drug benefit as primary endpoints in pivotal trials 
for both conditional and regular pathways to market 
authorisation.11 88 In addition, any demonstration 
of a statistically significant difference in survival 
between treatments, however small and regardless 
of whether such a difference is clinically meaningful 
to patients, has recently been accepted as the basis 
for approving new cancer drugs.89 To a large extent, 
regulatory evidence standards determine the clinical 
value of, and the quality of the evidence base for, new 
oncology drugs. Our study suggests these standards 
are failing to incentivise drug development that best 
meets the needs of patients, clinicians, and healthcare 
systems.15 17 19 21
Though surrogate endpoints are argued to have 
the advantage of allowing quicker drug development 
and patient access, it is questionable whether studies 
based on surrogate measures of efficacy provide 
optimal, or even meaningful, information for patients 
and clinicians.24 Moreover, our analysis raises the 
possibility that regulatory and current research 
practices have created a situation in which critical 
information about the outcomes that matter most 
to patients might never be generated once oncology 
drugs are approved for widespread use. The limited 
availability of studies showing either benefits to 
overall survival or quality of life in the postmarketing 
period underscores the importance of requiring robust 
evidence of clinical benefit at the time of marketing 
authorisation.90-92
The EMA and other drug regulatory agencies should 
reconsider when, and to what extent, it is appropriate 
to approve new cancer drugs on the basis of surrogate 
endpoints. Furthermore, when gains in survival 
and quality of life are shown, these gains should be 
meaningful to patients and clinicians.
Conclusion
Among 68 cancer drug indications approved by the 
EMA in the period 2009-13, and with a median of 
5.4 years’ follow-up, only 35 (51%) were associated 
with significant improvement in survival or quality of 
life over alternative treatment options, placebo, or as 
add on treatment. For 33 (49%), uncertainty remains 
over whether the drugs extend survival or improve 
quality of life. Of the 23 drugs with a survival benefit 
that could be scored with the validated ESMO-MCBS 
tool, only 11 (48%) were judged to offer a clinically 
meaningful benefit.
Most new oncology drugs authorised by the EMA in 
2009-13 came onto the market without clear evidence 
that they improved the quality or quantity of patients’ 
lives, and, when survival gains over available 
treatment alternatives were shown, they were not 
always clinically meaningful. Little new information 
to guide patients, their treating clinicians, or 
decisions about whether or not to pay for treatments 
was generated in the postmarketing period. This 
situation has negative implications for patients and 
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public health.19 93 When expensive drugs that lack 
clinically meaningful benefits are approved and 
paid for within publicly funded healthcare systems, 
individual patients can be harmed, important societal 
resources wasted, and the delivery of equitable and 
affordable care undermined.
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